Free-To-Play Fantasy MMORPG Mabinogi Celebrates Its 14th Anniversary On March 27!
24.3.2022 22:00:00 EET | Business Wire | Press release
Today, leading game publisher Nexon announced its venerable free-to-play fantasy MMORPG Mabinogi will be celebrating its 14th anniversary on March 27. Players will be able to engage in celebratory bonuses and activities for the game’s anniversary through April 14. As part of continuing quality of life improvements, Mabinogi will also be merging servers on April 14, so that global players can continue to embark on mystical adventures together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005803/en/
Mabinogi (Graphic: Business Wire)
The 14th anniversary celebration will include an abundance of updates from equipment repair cost reduction to 20% of the original price to Crom Bás dungeon polishing such as increased drop rate and overall dungeon length reduction. Additionally, the celebration brings a range of prizes, new missions and quests, starting on March 17, including:
- 14th Anniversary Night Bazaar - Meet Dero the Eventsman near Festia’s Main Gate and register your main character to participate in this guide quest, receive prizes, and play mini-games. Plus, all characters will be able to receive a 14th Anniversary Check design when issuing a check from the Tir Chonaill bank.
-
14th Anniversary Quests
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- Daily Quests: Finding Fruitful Fulfillment - Every day brings a different task for players to compete around the Night Bazaar for rewards. Players will be able to receive Cotton Candy from the Dessert Merchant, play in a variety of mini-games, and embark on great adventures by entering the Cave of Trials.
-
Bazaar Experience - This achievement quest rewards players with a special Festival Souvenir Hebona Robe sewing pattern with the opportunity to win a Festival Commemorative Luxury Equipment Bag Box, 20,000 EXP, and 25 instant prize tickets after completing all objectives.
- 14th Anniversary Hotdays - Players will be able to receive a special 14th Anniversary On-Time Gift Box every week and receive 10 Night Bazaar Stickers every weekend on Saturday and Sunday by logging in during the event.
- Festia Instant Prize Event - Try your luck at the Capsule Machine, located next to Fez in Festia, to open the Instant Prize window with 20,000 gold or one Instant Prize Ticket, which can be gained by participating in certain 14th Anniversary events.
On the heels of the 14th anniversary celebratory activities, players should expect Mabinogi servers to fully integrate on April 14. A new server, Erinn, will be launched on this date. It’s an exciting time to join the world of Mabinogi!
For more information on Mabinogi’s 14th anniversary and server merge, visit the official website and follow @mabinogi on Facebook for the latest updates.
Assets: Anniversary image | Server Merge image
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005803/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom